Ozempic vs Mounjaro: Key Differences, Which Is Better for Weight Loss?

Understanding the Brands: What Are Ozempic and Mounjaro?

Ozempic and Mounjaro are the two best-known injectable weight management medications on the market, yet they are frequently confused or conflated in public discussion. Understanding what each drug actually is — and is not — helps clarify why they perform differently and why one may be better suited to your specific situation.

Ozempic is a brand name for semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist manufactured by Novo Nordisk. Ozempic itself is FDA-approved for the treatment of type 2 diabetes and for reducing cardiovascular risk in people with established heart disease. It is administered as a weekly subcutaneous injection at doses of 0.5mg, 1mg, or 2mg. Although Ozempic is approved for diabetes, it is widely prescribed off-label for weight loss. Novo Nordisk's dedicated obesity formulation is Wegovy, which delivers semaglutide at 2.4mg weekly — a higher dose than available through standard Ozempic.

Mounjaro is a brand name for tirzepatide, manufactured by Eli Lilly. It is FDA-approved for the treatment of type 2 diabetes. Its obesity-focused counterpart, approved by the FDA in late 2023, is Zepbound. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. This dual mechanism sets it apart from semaglutide and all single GLP-1 agonists, producing synergistic appetite suppression and metabolic effects.

The key takeaway: these are different molecules with different mechanisms. Semaglutide is a single GLP-1 agonist; tirzepatide is a dual GIP/GLP-1 agonist. This fundamental difference drives the gap in their clinical outcomes. For deeper background on each drug individually, explore our complete semaglutide guide and our complete tirzepatide guide.

Weight Loss Efficacy: The Data Side by Side

Weight loss efficacy is where Mounjaro and Ozempic diverge most meaningfully. Both are effective — significantly more effective than any older weight loss drugs — but tirzepatide's dual mechanism produces consistently superior outcomes across multiple studies.

Semaglutide's efficacy was established through the STEP clinical trial program. In STEP 1, the landmark weight loss trial, participants receiving semaglutide 2.4mg (Wegovy dose) lost an average of 14.9% of body weight over 68 weeks. This was remarkable — a 15% weight reduction was previously achievable mainly through bariatric surgery or extreme interventions. For more detail on these studies, read our semaglutide clinical results article.

Tirzepatide's efficacy comes from the SURMOUNT trials. In SURMOUNT-1, participants receiving the maximum dose of tirzepatide (15mg) lost an average of 22.5% of body weight over 72 weeks. Even at lower doses — 5mg and 10mg — participants lost 15% and 19.5% respectively. Critically, 57% of participants on the 15mg dose lost at least 20% of body weight, a threshold that had been associated exclusively with surgical interventions.

While there is no direct randomized controlled trial comparing semaglutide and tirzepatide head-to-head for weight loss in non-diabetic patients, indirect comparisons and the SURPASS-CVOT data in diabetic patients consistently show tirzepatide producing 3–5 percentage points more weight loss on average. Network meta-analyses align with this conclusion. For a full side-by-side comparison, see our dedicated tirzepatide vs semaglutide comparison.

Blood glucose reduction is another dimension of comparison, particularly relevant for patients with type 2 diabetes. In SURPASS-2, a direct head-to-head trial, tirzepatide produced significantly greater HbA1c reductions than semaglutide 1mg (not the full 2.4mg Wegovy dose). Patients on tirzepatide 15mg reduced HbA1c by 2.58% on average versus 1.86% with semaglutide 1mg. This makes Mounjaro a strong choice for patients managing both weight and blood sugar.

Side Effects: How Do They Compare?

Both Ozempic and Mounjaro share a similar side effect profile, which reflects their common GLP-1 mechanism. The most frequently reported side effects for both drugs are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These effects are most pronounced during the dose titration period — the weeks or months when the dose is gradually increased — and tend to diminish substantially as the body adapts.

In STEP 1 trials, approximately 44% of semaglutide participants reported nausea, and about 25% reported vomiting. Diarrhea affected roughly 30% of participants. These numbers sound alarming, but severity matters: most patients describe the nausea as mild to moderate and temporary, not a reason to discontinue. Only about 7% of semaglutide users in trials discontinued due to GI side effects.

Mounjaro's trials show comparable GI rates, with nausea occurring in approximately 30–45% of participants depending on the dose, and vomiting in about 20–25%. At the higher tirzepatide doses (10mg and 15mg), GI side effects may be slightly more pronounced than equivalent semaglutide dosing — a likely consequence of the additional GIP pathway activation and greater overall metabolic effect.

Both medications carry FDA warnings for rare but serious risks including pancreatitis, gallbladder problems (particularly gallstones), and a theoretical risk of thyroid C-cell tumors observed in animal studies. To date, no increased incidence of thyroid cancer has been confirmed in human clinical trials for either medication. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use either drug.

For strategies on managing GI side effects from either medication, see our side effects management guide.

Cost and Insurance Coverage

Cost is often the deciding factor between Ozempic and Mounjaro, and unfortunately, neither comes cheap. At retail without insurance, Ozempic typically costs $900–$1,100 per month, while Mounjaro runs approximately $1,000–$1,300 per month. Wegovy and Zepbound (the obesity-specific formulations) carry similar or slightly higher price points.

Insurance coverage varies dramatically. Ozempic is more frequently covered for type 2 diabetes patients since it has older, broader approval. Mounjaro, being newer, may face more prior authorization hurdles. For weight loss (not diabetes), coverage of Wegovy and Zepbound is improving but inconsistent — many commercial plans still exclude obesity medications, though this is slowly changing as obesity is increasingly recognized as a chronic disease requiring medical treatment.

Novo Nordisk offers the NovoCare savings program for Ozempic and Wegovy, which can reduce costs for eligible commercially insured patients significantly. Eli Lilly offers savings cards for Mounjaro and Zepbound. For patients without adequate insurance coverage, compounded alternatives represent the most practical cost solution. Compounded semaglutide (the Ozempic/Wegovy active ingredient) is available from licensed telehealth platforms like Trimi for $200–$400 per month. For full cost analysis, visit our weight loss injection costs guide or our cost guide hub.

Approved Indications: What Each Drug Is Actually For

This is one of the most misunderstood aspects of both medications. The brand names Ozempic and Mounjaro are specifically approved for type 2 diabetes management and cardiovascular risk reduction — not for obesity treatment per se. The FDA's obesity-approved formulations are Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide 2.5–15mg), both marketed specifically for chronic weight management in adults with obesity or overweight with comorbidities.

In practice, the distinction between Ozempic and Wegovy matters primarily for insurance and cost. Prescribing Ozempic off-label for weight loss is legal and common — the drug itself is identical to Wegovy in its lower doses; the key difference is the maximum dose (Wegovy goes to 2.4mg, Ozempic tops out at 2mg). Similarly, Mounjaro and Zepbound contain the same tirzepatide molecule at the same doses; the difference is primarily the indication on the label and packaging.

For the cardiovascular risk indication, only Ozempic (semaglutide) currently carries approval for reducing major cardiovascular events in people with established heart disease — supported by the landmark SELECT trial. Mounjaro/Zepbound cardiovascular outcomes data is accumulating through the SURMOUNT-MMO trial, with results continuing to emerge in 2025–2026. The GLP-1 complete guide covers cardiovascular considerations in depth: GLP-1 complete guide.

Who Should Choose Ozempic vs Mounjaro?

Both medications require a prescription and medical supervision. If you're evaluating your options, Trimi's medical team conducts individualized assessments to determine which medication and dose is most appropriate for your health profile. Visit our treatments page to see what's available, or learn more on our how it works page.

For patients concerned primarily about long-term safety, our article on GLP-1 long-term safety reviews the evidence for both medications over extended periods.

Compounded Alternatives to Ozempic and Mounjaro

For patients who cannot afford brand-name pricing — $900–$1,300 per month — compounded versions of both active ingredients represent a significant cost-saving alternative. Compounded semaglutide is available from many licensed telehealth platforms at $200–$400/month. Compounded tirzepatide is also available, typically at $250–$450/month, though sourcing quality compounded tirzepatide requires more diligence in selecting a reputable, PCAB-accredited pharmacy.

Compounded formulations use the same active ingredient and rely on the same clinical evidence for efficacy. The key considerations are pharmacy quality and regulatory compliance. Our detailed breakdown on this topic is at compounded vs brand-name semaglutide. For affordable access options, see our affordable GLP-1 injections guide.